Nanotechnology in Medicine: From Inception to Market Domination

<table class="table-group" width="800px"><tr class="fig-image" id="fig2a"><td><img alt="389485.fig.002a" src="https://static.hindawi.com/articles/jdd/volume-2012/389485/figures/389485.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Venture capital funding of nanotechnology in 2007. Total investment amount: USD 702 millions. Fundings spread across 61 deals. Investment average size: $11.51 million</td></tr></table></td></tr><tr class="fig-image" id="fig2b"><td><img alt="389485.fig.002b" src="https://static.hindawi.com/articles/jdd/volume-2012/389485/figures/389485.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Venture capital funding of nanotechnology in 2009. Total investment amount: USD 792 millions. Fundings spread across 91 deals. Investment average size: $8.6 million</td></tr></table></td></tr></table>

<table>Venture capital investors. Captivated by the great potential of future development, in only two years VCs have shifted their focus on the “science of the tiny things”, nearly doubling investments in this sector.</table>

Journal of Drug Delivery

Nanotechnology in Medicine: From Inception to Market Domination

Figure 2